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ABSTRACT The evidence base concerning the management of benign pleural effusions has lagged
behind that of malignant pleural effusions in which recent randomised trials are now informing current
clinical practice and international guidelines.
The causes of benign pleural effusions are broad, heterogenous and patients may benefit from
individualised management targeted at both treating the underlying disease process and direct
management of the fluid. Pleural effusions are very common in a number of non-malignant pathologies,
such as decompensated heart failure, and following coronary artery bypass grafting. Pleural fluid analysis
forms an important basis of the diagnostic evaluation, and more specific assays and imaging modalities are
helpful in specific subpopulations.
Options for management beyond treatment of the underlying disorder, whenever possible, include
therapeutically aspirating the fluid, talc pleurodesis and insertion of an indwelling pleural catheter.
Randomised trials will inform clinicians in the future as to the risks and benefits of these options
providing a guide as to how best to manage patient symptoms in this challenging clinical setting.
@ERSpublications
Benign pleural effusion management is challenging and based on limited evidence. Treatment
options are discussed http://ow.ly/10EOSN
Introduction
The management of malignant pleural effusions has seen considerable progress within the past decade,
with a number of randomised controlled trials now informing practice [1–3]. This progress, by contrast,
has not been mirrored in non-malignant pleural disease, which has an evidence base still formed largely of
observational studies. As a result, the management of non-malignant pleural effusions is often guided by
techniques established and validated in malignant disease. Similarly, though international guidelines
produced by the British Thoracic Society and American Thoracic Society are available for malignant
pleural effusions [4, 5], no such equivalent guidelines exist for non-malignant pleural disease.
Copyright ©ERS 2016. ERR articles are open access and distributed under the terms of the Creative Commons
Attribution Non-Commercial Licence 4.0.
Previous articles in this series: No. 1: Psallidas I, Kalomenidis I, Porcel JM, et al. Malignant pleural effusion: from
bench to bedside. Eur Respir Rev 2016; 25: 189–198. No. 2: Bhatnagar R, Corcoran JP, Maldonado F, et al. Advanced
medical interventions in pleural disease. Eur Respir Rev 2016; 25: 199–213.
Received: March 09 2016 | Accepted after revision: April 03 2016
Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com
Provenance: Submitted article, peer reviewed.
Eur Respir Rev 2016; 25: 303–316 | DOI: 10.1183/16000617.0026-2016 303
SERIES
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The potential causes of non-malignant pleural effusions are numerous, often uncommon and in some
cases poorly understood. This lack of clear classification and definition may, in part, explain the absence of
high-quality evidence and established guidelines. As affected patients frequently have comorbidities and
their pleural effusions may be a manifestation of a disease process managed by non-respiratory specialists,
close multidisciplinary links are particularly important in this patient group to ensure coordinated and
optimised care pathways.
The purpose of this article is to outline the burden and spectrum of non-malignant pleural effusions and
to summarise the evidence base for management strategies.
Epidemiology
Non-malignant pleural effusions are common and the spectrum of disease is broad. In particular, pleural
effusions related to heart failure are frequently present in adult patients admitted to hospital and those in
critical care settings. Many of these effusions may be subclinical and resolve in parallel with treatment of
the underlying disease process. However, there is a substantial burden of symptomatic disease requiring
dedicated treatment.
Unpublished audit data from Bristol (UK) of 327 patients with non-malignant effusions referred to a tertiary
pleural service for further investigation over a 5-year period are shown in table 1. This data demonstrates the
distribution of possible aetiologies after effusions caused by malignancy or trauma have been excluded.
Evaluation of a pleural effusion
The evaluation of pleural disease relies upon a careful history and examination but will frequently
necessitate imaging and pleural fluid analysis in order to narrow the differential diagnosis.
The most common symptom resulting from a pleural effusion is breathlessness. The extent of
breathlessness may be disproportionate to the size of the effusion and influenced by coexistent cardiac and
lung diseases. Dyspnoea may result from a reduction in normal diaphragmatic movement in addition to
the reduction in tidal volume directly associated with the mass effect of fluid within the thoracic cavity [6].
The speed of onset of symptoms (most typically breathlessness) will frequently provide a steer to the
probable underlying cause, although accompanying radiology may provide an objective assessment of this.
Table 2 details common features in the patient’s history that may be relevant.
Pleural fluid analysis
Pleural fluid analysis will often provide crucial information in the evaluation of a non-malignant pleural
effusion, in addition to helping establish whether further investigations for malignancy are required.
Table 2 details the components of standard testing of pleural fluid and blood and those more targeted
assays, which may be indicated in specific cases of suspected non-malignant effusions.
Factors dictating the use of advanced tests may arise from the appearance of the fluid or patient factors
specific to the case. Fluid with a milky appearance, for instance, increases the possibility of a chylothorax
TABLE 1 Proportions of causes of non-malignant pleural effusions
Condition Patients
Pleural infection# 131 (40.0%)
Congestive cardiac failure 81 (34.8%)
Idiopathic pleuritis/undiagnosed 41 (12.5%)
Benign asbestos pleural effusion 27 (8.3%)
Liver cirrhosis 13 (4.0%)
Renal failure 10 (3.1%)
Pulmonary embolism 6 (1.8%)
Post-coronary artery bypass graft 4 (1.2%)
Drug reaction 3 (0.9%)
Rheumatoid effusion 3 (0.9%)
Trapped lung 2 (0.6%)
Pancreatitis 2 (0.6%)
Other¶ 4 (1.2%)
#: e.g. parapneumonic effusions, empyema or tuberculous pleural effusions; ¶: e.g. peritoneal dialysis,
systemic lupus erythematosus or a result of paint inhalation.
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and should be evaluated with a request for triglyceride and cholesterol levels and the presence or absence
of chylomicrons. Allowing the fluid to stand on a bench for 30 min can also be helpful in differentiating
empyema from chylothorax, as a clear supernatant will develop in empyema whereas a chylous effusion
will remain uniformly cloudy.
Although the criteria of Light is not completely specific or sensitive for the identification of a malignancy, an
effusion classified as a transudate by this criteria is strongly suggestive of a non-malignant cause and
specifically raises the possibility of an effusion due to heart failure, renal failure or a hepatic hydrothorax [8]. It
should, however, be noted that ∼5% of malignant pleural effusions are initially classified as a transudate
according to the criteria of Light [9].
TABLE 2 History, pleural fluid assays and other investigations used in the evaluation of
non-malignant pleural effusions
Category Details
History
Presenting symptoms Speed of onset
Other respiratory symptoms
Associated multisystem symptoms
Symptoms of bacterial or viral infection
Symptoms of connective tissue disease
Past medical history Previous thoracic surgery
Heart failure
Liver cirrhosis
Renal failure
Connective tissue disease (e.g. rheumatoid arthritis)
Lymphangioleiomyomatosis
IgG4-related disease
History of pleural infection
Drug history Medications associated with pleural disease
Immunomodulatory treatment
Ovarian hyperstimulation
Social history Cigarette smoking
Travel history
Occupational history Asbestos exposure
Other industrial exposure (e.g. beryllium) [7]
Inhaled allergens
Investigations
Standard pleural assays Protein
Lactate dehydrogenase
Glucose
Differential cell count
Advanced pleural assays Amylase
Triglycerides
Cholesterol
Microscopy for chylomicrons
Adenosine deaminase
Creatinine
N-terminal pro-brain natriuretic peptide#
Other investigations Full blood count
Urea and electrolytes
Liver function
Inflammatory markers
Autoimmune screen
N-terminal pro-brain natriuretic peptide
Urine analysis
#: serum levels correlate closely with pleural fluid levels; therefore, measurement of pleural fluid levels is
usually unnecessary.
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Pleural infection is typically indicated by low pH or low glucose, the values of which are correlated [10].
However, these fluid characteristics may also be seen in effusions due to rheumatoid arthritis, advanced
malignancy and oesophageal perforation [11].
Differential cell counts are not universally tested in all laboratories, but provide useful information. Pleural
effusions are commonly lymphocyte predominant, though the presence of significant numbers of neutrophils
and eosinophils may help narrow the possible diagnoses. Typically, chronic pleural effusions are predominantly
occupied by lymphocytes, and those due to more acute processes with neutrophils. The presence of eosinophils
is often associated with air or blood in the pleural space, but other diagnostic possibilities remain [12].
Standard blood biochemistry for a pleural effusion is likely to consist of a full blood count, urea and
electrolytes, liver function, coagulation assays and C-reactive protein. More specific tests including
N-terminal pro-brain natriuretic peptide (NT-proBNP) and assays such as a rheumatoid factor,
autoimmune profile and anti-neutrophil cytoplasmic antibody may be indicated in specific cases.
In many cases of non-malignant effusions, the diagnosis may be clear following an initial assessment and
the examination of pleural fluid, though in a substantial number of patients more detailed investigations
may be required.
Imaging
Chest radiographs and thoracic ultrasound play key roles in the evaluation and management of pleural
effusions [13]. Pleural appearances seen on computed tomography (CT) in patients with non-malignant
disease may be more subtle than in those with malignant findings. In the quantification and characterisation
of pleural effusions and pleural thickening, CT is, however, an invaluable tool. The value of using late venous
phase intravenous contrast has been demonstrated in characterising pleural thickening and identifying the
presence of malignant pleural disease [14]. Pleural fluid aspiration or drainage prior to CT imaging has been
shown to not significantly improve diagnostic performance in the evaluation of pleural pathology [15].
Magnetic resonance imaging (MRI) does not currently have a routine role in the evaluation of pleural
disease but provides high-quality imaging of chest wall invasion in malignant disease, which is reflected in
its use for malignant mesothelioma. It may be useful in younger patients and in patients in whom chest
wall soft tissue abnormalities are suspected. MRI has been demonstrated to aid characterisation of pleural
effusions as transudates and simple or complex exudates [16]. MRI scanning and lymphoscintigrams can
be very useful in demonstrating the site of the leak from the lymphatic system in cases of chylothorax [17].
Tissue diagnosis
Pleural biopsy may be achieved as a closed procedure, in the case of radiologically guided percutaneous
biopsy, or performed under direct visual guidance in the case of thoracoscopy. The sensitivity of
CT-guided biopsy in establishing pleural malignancy has been shown to be superior to Abrams’ biopsy
(87% versus 47%) [18], though in regions with a high prevalence of tuberculosis Abrams’ biopsies may still
have a role in view of the greater sensitivity they exhibit in the diagnosis of tuberculosis (82%) [19].
Thoracoscopic procedures may range from a single-port procedure undertaken with local anaesthetic and
sedation to multiple port video-assisted thoracoscopic surgery (VATS) under general anaesthetic. The
question as to which of these procedures should be undertaken may depend on local availability and
patient factors, which may suggest a more or less invasive approach being favoured.
The rationale for performing a biopsy is usually to specifically exclude malignancy, although they may also
be useful in establishing certain non-malignant diseases. The histopathological features of many
non-malignant effusions are typically nonspecific and a biopsy in isolation is unlikely to definitively
establish aetiology. However, notable exceptions exist, such as tuberculosis, which could be established
beyond doubt if mycobacteria are identified on pleural biopsies.
Effusion pathology
Pleural effusions are caused by a wide array of processes, a number of which are discussed below. Figure 1
demonstrates the multiple conditions and organ systems potentially involved in the development of a
non-malignant effusion, and their characteristic classification by Light’s criteria.
Pleural effusions develop due to an increase in production or a reduction in reabsorption of pleural fluid
or both processes in unison.
Cardiac
Heart failure leads to pleural effusion formation due to an increase in pulmonary capillary pressure and a
consequent leak into the pleural space. This arises as a result of a range of cardiac pathology including left
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ventricular dysfunction, which may be diastolic or systolic, valve dysfunction or constrictive pericarditis.
The prevalence of clinically identified heart failure is ∼3–20 cases per 1000 population and increases
markedly with age [20]. Of those patients with decompensated heart failure requiring diuretic treatment,
87% have pleural effusions on CT [21]. Patients with uncomplicated heart failure with pleural effusions
have bilateral effusions in 73% of cases [22]. A large proportion of these pleural effusions will improve
with optimised treatment for heart failure. A prospective study of 60 patients demonstrated that 89% of
those patients with an initial response to diuretic treatment no longer had a pleural effusion after 2 weeks
of follow-up [21]. Treatment typically involves medication, such as diuretics, angiotensin converting
enzyme inhibition, β-blockade, or procedures such as cardiac resynchronisation or intervention to treat
valve dysfunction. In recent decades considerable advances have been made in the management of heart
failure, resulting in a shift away from patients presenting with acute decompensated disease towards a
more stable and chronic course.
Although more commonly associated with left-sided failure, pleural effusion also occurs in right-sided heart
failure. Though they are most commonly small effusions, ∼13% of patients with idiopathic or familial
pulmonary artery hypertension have pleural effusions attributed to right-sided heart failure [23]. The process
of accumulation of the fluid is thought to be due to processes including decreased pleural fluid reabsorption,
increased hydrostatic pressure in bronchial veins, or dilated pulmonary arteries obstructing lymphatic flow.
These effusions appear to be most commonly right sided (58%) or bilateral (26%), and are typically
transudates [23]. Patients with cardiac effusions treated with diuretics are reported to have an increased pleural
fluid protein level relative to its blood level, resulting in the effusion being classified as an exudate by Light's
criteria [24]. In patients with an exudative effusion suspected of having a cardiac cause, correlation with
echocardiography or NT-proBNP measurement may be helpful to clarify the aetiology; care should be taken to
exclude other relevant potential causes, such as malignancy or pulmonary emboli.
Direct management of pleural effusions due to heart failure may be hampered by the presence of bilateral
effusions. However, despite isolated right- or left-sided effusions being uncommon, bilateral effusions
frequently have a larger left- or right-sided component [22]. In view of the dyspnoea associated with heart
failure itself, patients may benefit considerably from drainage of effusions that persist despite optimised
heart failure treatment.
Pleural effusions are present in nearly all patients immediately after coronary artery bypass grafting and
diminish over time, with the majority of early effusions remaining small and not a cause of significant
symptoms [25, 26]. Pleural effusions following coronary artery bypass grafting may be categorised as early or
late effusions, which are thought to be distinct processes, with early effusions more likely to be haemorrhagic,
eosinophil predominant and associated with a high LDH level, and later effusions more likely to be
non-haemorrhagic and characterised by a lymphocyte predominant, inflammatory-mediated process [27].
Of those patients with a persistent pleural effusion after coronary artery bypass grafting, many only require
a single thoracentesis with more long-term treatment rarely required [28]. Pleural effusions also occur as a
manifestation of post-cardiac injury (or Dressler’s) syndrome [29].
Heart failure
Pulmonary embolism
Exudates Transudates
Trapped lung
Pancreatitis
Rheumatoid arthritis
Liver cirrhosis
Renal failure
Nephrotic syndrome 
and hypoalbuminaemia
FIGURE 1 Schematic diagram illustrating a range of multisystem pathologies leading to non-malignant
effusions, categorised by their tendency to cause exudates or transudates.
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Hepatic
Hepatic hydrothorax is present in ∼5% of patients with liver cirrhosis and ascites [30]. Hepatic
hydrothoraces are most commonly right sided, although they may be bilateral or exist solely on the left [31].
This tendency towards the right side is thought to be due to a predisposition of diaphragmatic defects
affecting the right hemidiaphragm [32]. In the presence of such a defect, the negative intrathoracic pressure
results in a flow of fluid from the abdomen to the chest.
Although less common, hepatic hydrothorax also occurs in the absence of clinically apparent ascites [31].
However, even in these patients a one-way flow of radiolabelled colloid across the diaphragm has been
demonstrated, suggesting that in these patients flow across the diaphragm matches the rate of ascites
formation [33].
The presence of hepatic hydrothorax in liver cirrhosis is associated with a particularly poor prognosis. In a
study of 77 patients with hepatic hydrothorax, only 33 (43%) survived for 1 year after diagnosis [31].
Hepatic hydrothorax is managed with salt restriction and diuretic therapy, and treatment of ascites may
result in an improvement in the quantity of fluid above the diaphragm. Surgical repair of the diaphragm is
used, though more commonly, in the presence of persisting fluid, a trans-jugular intrahepatic portosystemic
shunt or liver transplant may be needed. If these procedures are ineffective, unavailable or contraindicated,
direct removal of pleural fluid may be required. Additionally, some centres are using indwelling pleural
catheters as a bridge to more definitive management, such as liver transplantation.
Fluid and protein loss is a concern that this particularly pertinent to patients with pleural effusions due to
hepatic hydrothorax and has given rise to the practice of administering intravenous human albumin
solution, as is used in patients with cirrhosis requiring paracentesis. Though no clear guidance or evidence
exists, use of human albumin solution is frequently advocated by hepatologists for patients with hepatic
hydrothorax, in whom the typically larger volume of fluid drained via an indwelling pleural catheter may be
a particular problem [34].
Renal
In a retrospective review of a cohort of 257 patients receiving long-term haemodialysis for renal failure, 52
(20%) patients had a history of pleural effusion [35]. These pleural effusions were most commonly due to
hypervolaemia (62%) and typically associated with bilateral transudative effusions. The remainder were
attributed to heart failure, uraemia or infection. An observational study of 430 patients with chronic
kidney disease (stage 3–5) established the incidence of pleural effusions to be 6.7%, substantially lower
than in patients with more severe disease necessitating renal replacement therapy [36].
Pleural effusions attributed to renal failure are typically bilateral and classified as transudates by Light’s
criteria. Of those patients who develop an exudative pleural effusion on long-term haemodialysis, the most
common cause is uraemic pleuritis, which may be unilateral and bilateral and develops in ∼4% of patients
on long-term dialysis. Uraemic pleuritis is typically associated with a blood stained effusion and biopsies
indicate fibrinous pleuritis [35].
Patients on long-term renal replacement therapy are likely to be more vulnerable to pleural infection given
the potential for a degree of immunodeficiency seen in these patients. The need to carefully exclude the
possibility of pleural infection is therefore an important consideration in this patient group.
Peritoneal dialysis represents an alternative process through which a pleural effusion may accumulate in
patients with renal failure [37]. This complication is reported to affect 1.6% of patients receiving chronic
ambulatory peritoneal dialysis and may be indicated by a reduction in the adequacy of peritoneal dialysis.
The development of pleural effusion may occur around the time of peritoneal dialysis initiation or much
later; 50% of effusions arise within 30 days of peritoneal dialysis initiation [38]. The biochemistry of
pleural fluid in such cases will characteristically represent the constituents of the peritoneal dialysate,
typically with very low protein and lactate dehydrogenase. Similar to the pleural fluid that accumulates in
liver cirrhosis due to diaphragmatic transit of ascites, right-sided pleural effusions due to peritoneal
dialysis are much more common. Recommended treatment options for pleural effusions due to peritoneal
dialysis consist of conservative measures, such as a temporary switch to haemodialysis, the use of more
frequent and smaller volume exchanges, chemical pleurodesis or surgical VATS [39].
Other causes
A wide variety of less common pathologies may cause a pleural effusion, the diagnosis of which may be
substantially less straightforward than those caused by heart, liver or renal failure, the underlying organ
failure of which is likely to be recognised prior to the development of the pleural effusion.
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Benign asbestos pleural effusion is a diagnosis of exclusion, with the possibility of mesothelioma needing
careful consideration, as it does in all patients with a history of asbestos exposure and pleural disease.
Benign asbestos pleural effusion is usually unilateral and characterised by an exudative effusion typically
occurring within 15 years of asbestos exposure, but may arise much later [40]. Effusions may be
asymptomatic or associated with breathlessness and chest pain and in around one-third of cases high
levels of eosinophils are present within the fluid [41]. Pleural biopsies are required to exclude malignancy,
and radiological follow-up over a 2-year period with chest CT is recommended in view of the need to
establish whether there is progressive abnormality and pleural thickening. Benign asbestos pleural effusion
is frequently associated with a transient effusion, for which long-term management may not be required.
Roughly 50% of patients with yellow nail syndrome have pleural effusions alongside lymphoedema,
chronic respiratory manifestations and the nail abnormalities themselves [42]. Pleural fluid analysis will
typically demonstrate a lymphocytic effusion, though some patients may develop a chylothorax. Biopsies
are likely to reveal a chronic fibrosing pleuritis [42].
Pulmonary embolism
Pleural effusions are a frequent finding in as many as 30% of patients with pulmonary embolism and are
thought to be due to ischaemia itself or cytokine release [43]. These effusions are, however, typically
present for no more than 1 month [44], and 90% are smaller than one-third of the hemithorax [45]. A
degree of breathlessness disproportionate to the size of the pleural effusion and pleuritic chest pain may be
a feature of effusions associated with pulmonary embolism.
Though pleural effusions are typically present on the same side as the lung affected by pulmonary embolism,
they may be unilateral despite bilateral embolic disease or bilateral when the pulmonary embolism is
unilateral. Surprisingly, the effusion is also present unilaterally and contralateral to the embolism in ∼7.5% of
patients with effusions due to pulmonary embolism [45].
Earlier studies with methodological limitations suggested that pleural effusions due to pulmonary emboli
may be transudates; however, more recent series have established that all pulmonary embolism-associated
effusions are exudates according to Light’s criteria [45]. Additionally pleural fluid is typically blood stained
and characteristically neutrophil predominant [45]. As these effusions are typically very small, a larger
effusion should potentially prompt evaluation for a concomitant cause.
Pancreatitis
An elevated pleural fluid amylase, indicated by either a pleural fluid amylase greater than serum amylase
or a pleural fluid amylase above the upper limit of normal for the serum value, is suggestive of acute or
chronic pancreatitis. Rupture of a pancreatic pseudocyst and fistula formation may result in direct
communication with the thoracic cavity and accumulation of pleural fluid.
Elevated pleural fluid amylase is also seen in effusions due to oesophageal rupture and possibly also in
malignant pleural effusions. Isoenzyme analysis may allow a distinction to be made between salivary and
pancreatic amylase in difficult cases.
Autoinflammatory
Rheumatoid arthritis is associated with a variety of pulmonary and pleural manifestations. A high
rheumatoid factor titre is predictive of pleural effusion alongside other extra-articular features. Rheumatoid
pleural disease is more common in men [46]. Though pleural effusions are described in 3–5% of patients
with rheumatoid arthritis, evidence of abnormalities on chest radiographs are much more common [47].
Pleural effusions associated with rheumatoid arthritis are typically painless, characterised as exudates and
have a low pH and glucose and may, therefore, be confused with pleural infection.
In patients with rheumatoid arthritis presenting with a pleural effusion, the possibility of medications
causing the effusion should be considered as a number of anti-rheumatoid therapies including
methotrexate, sulfasalazine and D-Penicillamine may be potentially implicated.
Systemic lupus erythematosus may give rise to pleural effusions directly through lupus pleuritis or through
a secondary process such as renal disease, heart failure or pulmonary embolism [47]. Pleural effusions
caused by lupus typically have a higher glucose level compared with those associated with rheumatoid
arthritis and may cause significant chest pain as part of the serositis syndrome. High anti-nuclear antibody
titres are sensitive but not specific for a lupus effusion; high antinuclear antibody titres may also be seen
in malignant pleural effusions [48]. However, lupus erythematosus cells are considered to be highly specific.
Connective tissue diseases such as systemic sclerosis, mixed connective tissue disease, granulomatosis with
polyangiitis, ankylosing spondylitis and Still’s disease may also have features of pleural involvement.
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Familial Mediterranean fever may cause pleural inflammation associated with unilateral pleuritic chest
pain and pleural effusions, which are most commonly small and short lived.
Chylothorax
A chylothorax may arise as a result of disruption of the thoracic duct in its path from the cisterna chyli up
the posterior mediastinum to the left subclavian vein. An interruption in the flow of chyle results in the
accumulation of fluid within the thoracic cavity. As the thoracic duct crosses the midline, a chylothorax
may be present in either hemithorax or bilaterally.
Around half of chylothoraces are due to trauma. Of the remainder, 38% are due to malignancy, most
commonly lymphoma or leukaemia. Non-malignant causes include congenital lymphatic disorders such as
Gorham or Milroy disease, or conditions such as lymphangioma, lymphangioleiomyomatosis, yellow nail
syndrome or lupus, or may be secondary to chylous ascites, most often a complication of liver cirrhosis [49].
Chylothoraces represent a different pathological mechanism to those shared by most other non-malignant
effusions, and warrant specific consideration. The diagnosis of a chylothorax is often made on the basis of
the typical appearance of fluid and easily established on the basis of pleural fluid biochemistry or the
presence of chylomicrons, but in some instances the appearance may be mistaken for a purulent effusion
due to infection. A reduced fat diet, if carefully adhered to, may reduce flow of chyle and result in
spontaneous closure of the thoracic duct defect. If unsuccessful, surgical ligation or percutaneous
embolisation approaches may be appropriate to directly block the chyle leak. Lymphoscintigraphy may be
helpful in the identification of the site of leak (figure 2).
Cholesterol effusions (or pseudochylous effusions) may have a similar milky appearance to a true chylous
effusion, but may be distinguished following the measurement of triglyceride and cholesterol levels. The
two most common causes of cholesterol effusions are tuberculosis and rheumatoid pleural disease;
helminth infections and cases secondary to malignancy occur less commonly [50].
Trapped lung
Trapped (unexpandable) lung may cause a pleural effusion through the development of a greater negative
pleural pressure, caused by visceral pleural thickening preventing lung expansion [51]. This negative
pressure facilitates movement from pleural capillaries into the pleural space. Frequently, the development
of trapped lung is a consequence of a pathological process already giving rise to a pleural effusion, after
which visceral pleural thickening perpetuates the effusion [52]. This process can occur in the context of a
long-standing effusion of any cause. However, a history of past pleural infection, thoracic surgery,
rheumatoid pleural disease, thoracic radiation or a haemothorax are described as potential causes [52].
a) b) c)
FIGURE 2 Lymphoscintigram and SPECT-CT (single photon emission computer tomography combined with
integrated low-dose computed tomography) imaging in a patient with a chylothorax. A 74-year-old man with
non-Hodgkin lymphoma had recurrence of a right-sided pleural effusion following previous talc pleurodesis.
An intercostal catheter was inserted and drained >3.5 L of milky fluid with a triglyceride level of 17 mmol·L−1,
confirming a chylothorax. Chyle flow decreased but continued despite total parental nutrition. Computed
tomography of the abdomen also indicated a confluent lymphomatous mass around the aorta and inferior
vena cava with ascites and lymphadenopathy. A lymphoscintigraphy was performed to determine the point of
chyle leakage. Tc99-labelled human serum albumin-DTPA was injected into the first pedal interdigital web
space bilaterally and serial whole body SPECT-CT was performed at intervals between 90 min and 6.5 h
following tracer administration. This case illustrates the importance of Tc99 lymphangioscintigraphy as it
identified an abdominal chyle leak site for the right chylothorax (instead of leakage at the thoracic portion of
the thoracic duct), and changed the management of the patient. The patient was referred for radiotherapy to
the abdominal mass. a) Lymphoscintigram showing a site of chyle leak in the abdomen at 2 h following
injection. b) Low dose SPECT-CT showed pooling of the tracer below the diaphragm confirming chyle leak
from the abdominal source into the abdomen. c) Follow-up lymphoscintigram showed tracer uptake over the
right pleural cavity, confirming that chyle leak from the abdomen migrated transdiaphragmatically causing
the right chylothorax at 6.5 h after injection. (Images courtesy of A. Yogendran, University of Western
Australia, Perth, Australia).
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Iatrogenic
Pleural effusions caused by medication are uncommon, though a wide range of medications may
potentially be implicated. More than 70 drugs have been reported to cause pleural effusions, and among
them are cardiovascular medications and ergoline drugs, as well as chemotherapy agents [53]. Drugs more
commonly associated include methotrexate, amiodarone and nitrofurantoin [13]. Mechanisms include
hypersensitivity, direct toxicity, free radical production and chemical-induced inflammation [54].
A number of drugs may cause an effusion through lupus pleuritis. Pleural fluid eosinophilia may alert the
clinician to the possibility of a drug-induced effusion, though this finding is neither sensitive nor specific.
In addition to drug causes, iatrogenic pleural effusions may also arise as a complication of therapeutic
interventions such as radiotherapy.
Pleural fluid may, in some cases, be exogenous fluid that accumulates within the pleural space, due to
either transit of fluid from another body cavity, such as in peritoneal dialysis or an iatrogenic consequence
of misplaced central venous catheters, oesophageal perforation, or in the case of spinal or urological
surgery an accumulation of cerebrospinal fluid or urine, respectively, within the pleural space. The
management of these processes will not be discussed here.
Treatment of non-malignant pleural effusions
The management of non-malignant pleural effusions is predominantly focussed on relief of symptoms.
The accumulation of a pleural effusion may significantly increase levels of dyspnoea in a patient with a
considerable pre-existing symptom burden from comorbid conditions. Non-malignant effusions, in and of
themselves, do not represent a significant mortality risk, but are the cause of substantial morbidity, the
adequate treatment of which relies on identification of the underlying disease.
Treatment of underlying aetiology
Treatment targeted at the underlying cause for pleural effusion accumulation is crucial. Such treatment
may attenuate or lead to complete resolution of the effusion. Additionally, in many cases such treatment
may alleviate symptoms or improve prognosis independently of the pleural effusion.
It is beyond the scope of this article to address the direct treatment of all potential pathologies that lead to
pleural effusions; therefore, the focus here will be on direct treatment of the effusion itself. In substantial
numbers of patients, direct intervention either to remove pleural fluid or to prevent its accumulation may
be required.
Targeted pleural fluid management
Pleural fluid aspiration may be required prior to definitively establishing an aetiology, and in other
patients is a consideration after a diagnosis has been confirmed. In a small number of patients, despite
best efforts, it may not be possible to reach a clear diagnosis and in others it may be that treatment
targeted at addressing symptoms may be a pragmatic approach preferred over and above ongoing and
potentially more invasive investigations, particularly in patients with a poor prognosis. Interestingly, the
removal of pleural fluid appears to result in an improvement in breathlessness not mirrored directly by the
degree of improvement in gas exchange [55].
The management options used for patients with non-malignant pleural effusions are closely aligned to
those used in patients with malignant disease, in whom the evidence base for the spectrum of available
treatments is frequently stronger.
Some non-malignant pleural effusion may require observation alone. Small and asymptomatic pleural
effusions occurring shortly after cardiac surgery for instance may well resolve spontaneously and any
non-malignant effusion reaching a steady state without causing symptoms should not require intervention.
Therapeutic aspiration
Therapeutic aspiration fulfils an important role in the management of any pleural effusion. At the time of
obtaining a pleural fluid sample for diagnostic purposes, a substantial volume may be removed for
therapeutic purposes. This should improve patient symptoms during the period in which diagnostic
evaluation may occur, allows evaluation of the speed of fluid build-up, provides evidence of the degree of
symptomatic improvement that can be gained through removal of fluid, and clarifies whether there is any
evidence of trapped lung which may direct future management.
In some patients, therapeutic aspiration may represent a legitimate therapeutic option in the long term.
Depending on the speed at which fluid re-accumulates, therapeutic aspirations may only be required at a
frequency acceptable to both clinicians and patients. The downside to this approach is that symptoms may
progressively worsen while fluid accumulates. As this strategy may be administered as an outpatient and
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with non-specialist equipment, it has little financial cost over and above that of the patient and clinician’s
time. However, the cumulative risk of bleeding and the introduction of infection during repeated
procedures should be considered. Though the risk of trapped lung developing in patients requiring
repeated therapeutic aspirations is uncertain, the possibility of the visceral pleura becoming thickened over
time as it is chronically bathed in pleural fluid is a potential disadvantage of this approach.
In malignant pleural effusions, a maximal volume of aspiration of 1.5 L is advised [4]. Though the risk of
re-expansion pulmonary oedema is low, caution should be advised when considering larger volume
aspirations and the mechanism causing re-expansion oedema also applies in non-malignant effusions.
Some authorities recommend the use of manometry as a guide to predict the appropriate volume to
remove [56]. In the absence of manometry then an appropriate strategy may be to aspirate only 1.5 L on a
single occasion, though if the patient experiences no symptoms such as cough or chest pain, it may be
reasonable to cautiously aspirate more than this volume on a case-by-case basis.
Indwelling pleural catheters
The PleurX catheter (CareFusion, Vernon Hills, IL, USA) was approved by US Food and Drug
Administration in 1997 for the management of malignant pleural effusions [57]. Since 2001, the license
has extended to additionally apply to non-malignant pleural effusions [58].
Indwelling pleural catheter use in malignant pleural effusions. Increasing evidence is now available
supporting the safe use of indwelling pleural catheters in malignant pleural disease, which allows
outpatient-based treatment. Use of indwelling pleural catheters in malignant disease is considered to be
cost-effective compared with talc pleurodesis (which necessitates an inpatient stay), though this is dependent
on expected prognosis [59, 60].
The use of indwelling pleural catheters in non-malignant effusions is not as well supported by available
evidence and a lack of familiarity with indwelling pleural catheters amongst the multidisciplinary team
involved in the care of these patients may contribute to their use not being as widespread. Whether
indwelling pleural catheters are cost-effective in non-malignant disease has not yet been established and
neither has the question of which patients with non-malignant effusions are likely to benefit most.
There are a number of observational studies reporting on the use of indwelling pleural catheters in
non-malignant disease, with the majority of studies including a range of patient groups rather than specific
disease groups in isolation. Complication rates associated with the use of indwelling pleural catheters in
non-malignant effusions appear similar to those seen in patients with malignant disease [34, 61]. A review
of available literature including 377 patients included in observational studies consisted of a varied case
mix, with largest contributions being those patients with congestive cardiac failure (40%), hepatic
hydrothorax (17%) or idiopathic pleuritis (15%). The most common complications were empyema or drain
site infection which occurred in 5.2% and 2.9%, respectively [61].
Pleurodesis may occur in patients treated with an indwelling pleural catheter without this being the
express purpose (figure 3). Often described as a “spontaneous” pleurodesis, this process occurs in around
one-third of patients with non-malignant effusions treated with an indwelling pleural catheter. The rate of
pleurodesis appears variable and dependent on the cause. The rate of spontaneous pleurodesis appears to
be particularly low in hepatic hydrothoraces [34].
a) b) c)
FIGURE 3 Chest radiographs of a patient with a transudative pleural effusion due to biopsy confirmed
systemic amyloidosis causing nephrotic syndrome. a) At presentation with right-sided pleural effusion.
b) Recurrent pleural effusion following attempted talc pleurodesis which was performed due to frequent
requirement for pleural aspiration. c) 6 months after placement of an indwelling pleural catheter. At this point
a reduction in the volume of fluid drained indicated a “spontaneous” pleurodesis and allowed drain removal.
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The use of indwelling pleural catheters in non-malignant effusions is the subject of a UK-based randomised
controlled trial (REDUCE), recruitment to which is ongoing (www.isrctn.co.uk ISRCTN66354436). This
study involves patients with symptomatic pleural effusions with heart failure or liver failure which persist
despite optimised treatment being randomised to either treatment with an indwelling pleural catheter or
therapeutic pleural aspirations as required. This study should, upon completion, provide robust data
regarding the risks and benefits and cost-effectiveness of indwelling pleural catheters in this population.
Pleurodesis
Pleurodesis is a long established, safe and effective technique validated in patients with malignant effusion.
As with the other techniques, there is less evidence to support its use in non-malignant effusions. A wide
array of pleurodesis agents have been used in non-malignant effusions, though talc is the best described.
Talc may be delivered via a chest drain (as a slurry) or at thoracoscopy (as poudrage).
There are historical concerns regarding talc containing traces of asbestos and reports of acute respiratory
distress syndrome associated with the use of non-graded talc, which may be pertinent in patients with
non-malignant disease. However, the use of contemporary French-graded talc allows these risks to be
mitigated [62]. Pleurodesis with ungraded talc with small particles (<10 µM) has been shown to be
associated with significantly greater levels of systemic inflammation and poorer gas exchange than graded
talc in which these small particles are removed [63].
A large retrospective study of 611 patients which evaluated the success of talc pleurodesis via chest drain
reported a success rate of 77% in the 68 patients with non-malignant causes. This study, however, did
exclude patients undergoing more than one attempt at pleurodesis and the specific aetiologies amongst the
included non-malignant effusions is not clear [64]. GLAZER et al. [65] reported a success rate of 75% with talc
pleurodesis in 16 non-malignant effusions of varying aetiology. A similar success rate of 80% was reported
by SUDDUTH et al. [66] using a range of pleurodesis agents in 25 effusions with non-malignant cause.
There is evidence from a small case series suggesting that the use of talc pleurodesis for patients with
hepatic hydrothorax is of considerable risk; the peri-procedure mortality is reported at 45.5% [67]. It is
unclear to what extent this result may be explained by an extremely comorbid patient population.
In patients with hepatic hydrothorax undergoing talc poudrage at thoracoscopy a success rate of only
47.6% was reported in a small case series of 21 procedures in 18 patients [68]. As was the case in patients
with hepatic hydrothorax receiving talc slurry pleurodesis via a chest tube, there were high rates of
mortality (38.9% mortality during the 3 month follow-up) as well as considerable morbidity and long
inpatient hospital stays.
Pleural-peritoneal and pleuro-venous shunts
Pleuro-peritoneal or pleuro-venous shunting of pleural fluid from the pleural space is a conceptually
attractive idea. A case series of 12 patients with non-malignant effusions treated with a shunt from the
pleural space to the subclavian or jugular vein reported promising results. The devices used consisted of a
Denver Shunt with an external manual pump and all devices remained patent other than in one patient
who experienced shunt occlusion at 4 weeks [69]. No air embolism was reported in this study, though this
mechanism would result in a pneumothorax or pneumothorax ex vacuo thus becoming a life-threatening
complication. Pleuro-venous shunting would mitigate against the protein and volume loss related to
external drainage of fluid, which hepatic hydrothorax patients may be particularly susceptible to.
Pleuro-peritoneal devices have been used successfully with evidence of effective symptomatic relief in both
malignant and non-malignant pleural effusions though are typically contraindicated in patients with
ascites [70–72]. In view of the pressure difference between the pleural and peritoneal space a pump is
required to achieve flow, and devices used have incorporated a unidirectional valve.
Surgical techniques
The frailty and comorbidity of some patients with non-malignant pleural effusion may act as a deterrent
against some more invasive techniques, but surgical pleurectomy may be an appropriate option in some
patients with a persistent effusion if less invasive techniques have been attempted and failed, or are
otherwise contraindicated.
Future directions
As life expectancies rise and the prevalence of comorbidity increases, an increase in the prevalence of
non-malignant pleural effusions should be expected. Treatments validated in malignant pleural disease
cannot be assumed to be effective in non-malignant disease and equally, strategies effective in the treatment
of a rheumatoid pleural effusion may not be so in a hepatic hydrothorax. Variations in the accepted
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techniques make randomised studies difficult to establish, particularly in respect of the management
representing standard care which in many cases is not universally accepted, or deemed appropriate across a
range of specialist centres.
Despite this, there is an increasing body of observational data and randomised studies are ongoing which
should provide high-quality evidence upon which to base practice. In the future, pleural disease guidelines
should be structured to include guidance on non-malignant pleural effusions alongside guidance for the
management of pleural infection and malignant pleural disease.
Conclusion
Non-malignant pleural effusions encompass a heterogenous group of multisystem pathologies. The
evaluation of such patients ranges from the straightforward patient with clinically obvious heart failure, the
management of whom may be clearly ascertained, through to complex disease processes, with a number of
contributing processes, through which meticulous investigation may be required. Relative to many other
areas of respiratory medicine, it is often said there is a lack of research in pleural disease and this is
particularly evident in non-malignant pleural disease which currently suffers from a lack of high-quality
data to guide management and future research should address this unmet need.
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